Apellis Pharmaceuticals Dirección
Dirección controles de criterios 3/4
El CEO de Apellis Pharmaceuticals' es Cedric Francois , nombrado en Sep 2009, tiene una permanencia de 14.58 años. compensación anual total es $9.20M, compuesta por 7.4% salario y 92.6% primas, incluidas acciones y opciones de la empresa. posee directamente un 1.57% de las acciones de la empresa, por valor de $90.20M. La antigüedad media del equipo directivo y de la junta directiva es de 5.8 años y 8.8 años, respectivamente.
Información clave
Cedric Francois
Chief Executive Officer (CEO)
US$10.4m
Compensación total
| Porcentaje del salario del CEO | 7.1% |
| Permanencia del CEO | 14.8yrs |
| Participación del CEO | 1.5% |
| Permanencia media de la dirección | 5.3yrs |
| Promedio de permanencia en la Junta Directiva | 8.9yrs |
Actualizaciones recientes de la dirección
Recent updates
What Apellis Pharmaceuticals, Inc.'s (NASDAQ:APLS) P/S Is Not Telling You
May 30
It's Probably Less Likely That Apellis Pharmaceuticals, Inc.'s (NASDAQ:APLS) CEO Will See A Huge Pay Rise This Year
May 30Apellis Pharmaceuticals Strives For Recovery Despite Syfovre Setbacks
May 14Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) First-Quarter Results: Here's What Analysts Are Forecasting For This Year
May 09Apellis Pharmaceuticals: Eye Disease Drug Syfovre On Comeback Trail - But Risks Remain
Feb 16With A 55% Price Drop For Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) You'll Still Get What You Pay For
Jul 19Analysts Are Betting On Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) With A Big Upgrade This Week
May 13Is Apellis Pharmaceuticals (NASDAQ:APLS) Using Debt In A Risky Way?
Apr 18Is Apellis Pharmaceuticals (NASDAQ:APLS) Using Debt Sensibly?
Dec 14Some Analysts Just Cut Their Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Estimates
Nov 09Apellis Pharmaceuticals: Trying To Develop A Blockbuster Franchise
Sep 28Apellis gains as FDA says AdCom unnecessary for eye disease candidate
Sep 07Is Apellis Pharmaceuticals (NASDAQ:APLS) A Risky Investment?
Aug 17Apellis to exchange $75.6M in convertible senior notes for common stock
Jul 27Análisis de compensación del CEO
| Fecha | Compensación total | Salario | Ingresos de la empresa |
|---|---|---|---|
| Mar 31 2024 | n/a | n/a | -US$417m |
| Dec 31 2023 | US$10m | US$735k | -US$529m |
| Sep 30 2023 | n/a | n/a | -US$606m |
| Jun 30 2023 | n/a | n/a | -US$657m |
| Mar 31 2023 | n/a | n/a | -US$691m |
| Dec 31 2022 | US$9m | US$681k | -US$652m |
| Sep 30 2022 | n/a | n/a | -US$634m |
| Jun 30 2022 | n/a | n/a | -US$638m |
| Mar 31 2022 | n/a | n/a | -US$702m |
| Dec 31 2021 | US$9m | US$647k | -US$746m |
| Sep 30 2021 | n/a | n/a | -US$520m |
| Jun 30 2021 | n/a | n/a | -US$460m |
| Mar 31 2021 | n/a | n/a | -US$360m |
| Dec 31 2020 | US$9m | US$619k | -US$345m |
| Sep 30 2020 | n/a | n/a | -US$536m |
| Jun 30 2020 | n/a | n/a | -US$470m |
| Mar 31 2020 | n/a | n/a | -US$423m |
| Dec 31 2019 | US$4m | US$560k | -US$305m |
| Sep 30 2019 | n/a | n/a | -US$228m |
| Jun 30 2019 | n/a | n/a | -US$194m |
| Mar 31 2019 | n/a | n/a | -US$156m |
| Dec 31 2018 | US$4m | US$550k | -US$128m |
| Sep 30 2018 | n/a | n/a | -US$109m |
| Jun 30 2018 | n/a | n/a | -US$85m |
| Mar 31 2018 | n/a | n/a | -US$64m |
| Dec 31 2017 | US$2m | US$400k | -US$51m |
Compensación vs. Mercado: La compensación total ($USD10.37M) de Cedric está en línea con el promedio de empresas de tamaño similar en el mercado US ($USD8.44M).
Compensación vs. Ingresos: La compensación de Cedric ha aumentado mientras la empresa no es rentable.
CEO
Cedric Francois (52 yo)
14.8yrs
Permanencia
US$10,373,049
Compensación
Dr. Cedric Francois, M.D., Ph.D. serves as Principal of Vista Therapeutics, Inc. Dr. Francois co-founded Apellis Pharmaceuticals, Inc. in 2009 and has been its Chief Executive Officer, President and Direct...
Equipo directivo
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| Co-Founder | 14.8yrs | US$10.37m | 1.51% $ 74.0m | |
| Co-Founder & Director | 15.4yrs | US$495.96k | 0.64% $ 31.3m | |
| CFO & Treasurer | 6.7yrs | US$3.74m | 0.084% $ 4.1m | |
| Chief Operating Officer | less than a year | US$3.71m | 0.023% $ 1.1m | |
| General Counsel | 10.4yrs | US$4.89m | 0.094% $ 4.6m | |
| Chief Medical Officer | 1.4yrs | US$4.43m | 0.0052% $ 253.3k | |
| Co-Founder & Chief Scientific Officer | 14.8yrs | US$3.08m | 0.92% $ 45.0m | |
| VP, Corporate Controller & Chief Accounting Officer | 2.8yrs | sin datos | 0.0085% $ 416.9k | |
| Senior Vice President | no data | sin datos | sin datos | |
| Chief People Officer | 4.1yrs | sin datos | 0.00073% $ 35.8k | |
| Head of Hematology Engagement & Member of PNH Scientific Advisory Board | 2.1yrs | sin datos | sin datos | |
| Senior Vice President | 5.3yrs | sin datos | 0.0031% $ 151.9k |
5.3yrs
Permanencia media
51.5yo
Promedio de edad
Equipo directivo experimentado: El equipo directivo de APLS es experimentado (5.8 años antigüedad media).
Miembros de la Junta
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| Co-Founder | 14.8yrs | US$10.37m | 1.51% $ 74.0m | |
| Co-Founder & Director | 14.8yrs | US$495.96k | 0.64% $ 31.3m | |
| Head of Hematology Engagement & Member of PNH Scientific Advisory Board | 8.9yrs | sin datos | sin datos | |
| Independent Chairman of the Board | 10.9yrs | US$504.08k | 0.00056% $ 27.4k | |
| Independent Director | 10.9yrs | US$488.46k | 0.00056% $ 27.4k | |
| Member of AMD Scientific Advisory Board | 8.9yrs | sin datos | sin datos | |
| Member of PNH Scientific Advisory Board | 8.9yrs | sin datos | sin datos | |
| Member of Pulmonology Scientific Advisory Board | 8.9yrs | sin datos | sin datos | |
| Independent Director | 4.2yrs | US$489.08k | 0.0047% $ 229.3k | |
| Independent Director | 14.3yrs | US$480.96k | 0.11% $ 5.3m | |
| Member of Pulmonology Scientific Advisory Board | no data | sin datos | sin datos | |
| Member of Pulmonology Scientific Advisory Board | 8.9yrs | sin datos | sin datos |
8.9yrs
Permanencia media
57.5yo
Promedio de edad
Junta con experiencia: La junta directiva de APLS se considera experimentada (8.8 años de antigüedad promedio).